Free Newsletter
Ebola vaccines readied for first human trials
Researchers are pushing ahead with the first human trials of an ebola vaccine. Typical vaccines spark an antibody response against a threat. But with the lethal ebola, a successful vaccine has to produce T-cells to make the immune system powerful enough vanquish the virus. And a vaccine is badly needed. A successful ebola vaccine would give health workers immunity as they fight against any outbreak, which is becoming increasingly likely.
"We are seeing more and more naturally-occurring human outbreaks of this deadly disease. With worldwide air travel and tourism, the virus can now be transported to and from remote regions of the world. And it has huge potential as a possible weapon of bioterrorism. We desperately need a protective vaccine," says Dr. Anthony Sanchez, of the U.S. Centers for Disease Control and Prevention.
- read the article in the Washington Post
Related Articles:
People, rainfall, biodiversity breed new diseases. Report
Emerging infectious diseases on the rise. Report
WHO: Infectious disease a growing threat. Report
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage


